Drug intelligence / Profile preview

MyoCell II

Development stage
Unknown
Lead developer
Bioheart
Modality
Cell Therapies, Gene Therapies
Administration
Intramyocardial
01

Overview

MyoCell II is a second-generation autologous cell therapy developed by Bioheart (now U.S. Stem Cell) for the treatment of congestive heart failure and chronic myocardial ischemia. The therapy consists of skeletal myoblasts harvested from the patient's own muscle tissue, which are then expanded ex vivo and genetically modified using a non-viral plasmid to overexpress Stromal Cell-Derived Factor-1 (SDF-1). Once injected intramyocardially, the myoblasts provide structural support to the damaged heart wall, while the secreted SDF-1 acts as a potent chemoattractant for endogenous stem and progenitor cells. This dual mechanism is intended to promote myocardial regeneration, enhance angiogenesis, and improve overall cardiac function in patients with heart failure following a myocardial infarction.

Brand names
MyoCell II
Other names
MyoCell SDF-1Autologous skeletal myoblasts expressing SDF-1SDF-1 modified myoblastsSDF1 modified myoblastsSDF 1 modified myoblasts
02

Targets

CXCR7 (CXC chemokine receptor 7)CXCR4 (C-X-C motif chemokine receptor 4)

Beyond the preview

Go deeper on MyoCell II.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on MyoCell II.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call